Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

Table 2

Discussing baseline tumor factors and relation to hormonal therapy interruption in regard to palbociclib dose reduction.

Parameters		Palbociclib dose reduction		Total	value
		No = 80	Yes = 70
ECOG PS	0	1	1	2	0.49
		50.0%	50.0%	100.0%
	1	55	54	109
		50.5%	49.5%	100.0%
	2	24	15	39
		61.5%	38.5%	100.0%
BMI	Normal	15	8	23	0.40
		65.2%	34.8%	100.0%
	Overweight	24	20	44
		54.5%	45.5%	100.0%
	Obese	41	42	83
		49.4%	50.6%	100.0%
Ki67 level	Low	48	38	86	0.78
		55.8%	44.2%	100.0%
	High	30	30	60
		50.0%	50.0%	100.0%
	NA	2	2	4
		50.0%	50.0%	100.0%
Menopausal status	Premenopause	39	39	78	0.39
		50.0%	50.0%	100.0%
	Postmenopause	41	31	72
		56.9%	43.1%	100.0%
Allred score	≤6	17	7	24	0.048
		70.8%	29.2%	100.0%
	7-8	63	63	126
		50.0%	50.0%	100.0%
Stage at diagnosis	Stage II	3	1	4	0.44
		75.0%	25.0%	100.0%
	Stage III	29	21	50
		58.0%	42.0%	100.0%
	Stage IV	48	48	96
		50.0%	50.0%	100.0%
(Neo) adjuvant chemotherapy	No	70	58	128	0.54
		54.7%	45.3%	100.0%
	Yes	10	11	21
		47.6%	52.4%	100.0%
PR-status	Negative	12	11	23	0.90
		52.2%	47.8%	100.0%
	Positive	68	59	127
		53.5%	46.5%	100.0%
Site of metastasis	Bone-only	15	17	32	0.41
		46.9%	53.1%	100.0%
	Others	65	53	118
		55.1%	44.9%	100.0%
Site of metastasis	Single	26	28	54	0.34
		48.1%	51.9%	100.0%
	Multiple	54	42	96
		56.3%	43.8%	100.0%
HER2 low status	No	47	36	83	0.37
		56.6%	43.4%	100.0%
	Yes	33	34	67
		49.3%	50.7%	100.0%